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Background. Patients aﬄicted with Alzheimer’s disease (AD) exhibit a decrease in the cerebrospinal ﬂuid (CSF) concentration
of the 42 amino acid form of β-amyloid (Aβ42). However, a high discrepancy between diﬀerent centers in measured Aβ42 levels
reduces the utility of this biomarker as a diagnostic tool and in monitoring the eﬀect of disease modifying drugs. Preanalytical
and analytical confounding factors were examined with respect to their eﬀect on the measured Aβ42 level. Methods. Aliquots of
CSF samples were either treated diﬀerently prior to Aβ42 measurement or analyzed using diﬀerent commercially available xMAP
or ELISA assays. Results. Confounding factors aﬀecting CSF Aβ42 levels were storage in diﬀerent types of test tubes, dilution with
detergent-containing buﬀer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantiﬁcation.
Conclusion. In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding
factors is warranted.
1.Introduction
By the year of 2000, it was estimated that more than 25
million people suﬀered from dementia, with Alzheimer’s
disease (AD) being the most common subtype accounting
for around 50 percent of all cases [1, 2]. Histopathological
hallmarks of AD include intracellular neuroﬁbrillary tangles
composed of tau protein and extracellular deposits of
neurotoxic β-amyloid (Aβ) visualized as amyloid plaques
[3–5]. The cerebrospinal ﬂuid (CSF) concentrations of
Aβ peptides in combination with the tau protein and its
hyperphosphorylated forms have been found to support the
clinical diagnosis of AD [6]. Not only do these biomarkers
fulﬁll the criteria for an ideal diagnostic test according to
the guidelines of the Working group on molecular and
biochemical markers of Alzheimer’s disease [7], but Aβ have
also been suggested to be a driving force in the disease
process. The amyloid cascade hypothesis proposes that an
imbalance in Aβ production and clearance leads to an
increase in Aβ load and that this initiates taupathology and
neuronaldegenerationwhichultimatelycausesdementia[8].
The hypothesis is derived from cases aﬀected by rare familial
forms of AD wherein mutations in the amyloid precursor
protein (APP) gene or in the presenilin-encoding (PSEN1
and PSEN2) genes, which are involved in metabolizing the
APP protein, invariably lead to AD pathology. The 42 amino2 International Journal of Alzheimer’s Disease
acid long form of Aβ (Aβ42) has also proven to be the best
established CSF biomarker for amyloid pathology in the
brain. Aβ has therefore become the primary target of many
clinical trials in their search for novel treatment strategies as
well as a core biomarker candidate for monitoring disease-
modifying eﬀects [9].
Recently a large multicenter study assessed the diagnostic
value of the 42 amino acid long form of Aβ (Aβ42), total
tau (T-tau), and tau phosphorylated at threonine 181 (P-
tau181) in identifying subjects with incipient AD among
patients with mild cognitive impairment (MCI) and they
were found to provide good accuracy [10]. The neuropatho-
logic correlates distinguishing those of the MCI patients
thought to await in the precedent stage of clinical overt AD
[11], are seemingly reﬂected by these biomarkers. Although
the biomarkers show reasonable accuracy to discriminate
controls from AD patients as well as prodromal AD in MCI
patients [12–15], it has been shown in population-based
studiesthathealthyelderlypeoplewholaterdevelopADhave
reductions in CSF Aβ42 levels while tau levels are normal
[16, 17]. However, there is a high discrepancy in the reported
concentrations of these biomarkers [18] leading to diﬀerent
cut-oﬀ values between diﬀerent centers with the highest
variability shown for Aβ42 [10]. This type of between-center
variability in analytical results may be due to diﬀerences in
preanalytical procedures for CSF collection and sample pro-
cessing, analytical procedures and techniques, and to batch-
to-batch variation for the immunoassay kits. It has been
suggested that preanalytical confounding factors such as CSF
collection, storage, and adsorption to tube-walls contribute
to the highest magnitude of errors [19]. This paper aims
at assessing these preanalytical confounding factors together
with other factors such as blood contamination, blood-brain
barrier dysfunction, sample pretreatment and diﬀerences in
assay performance regarding the impact on measured Aβ42
levels.
2.MaterialandMethods
2.1.CSFandPlasmaSamples. AllCSFsampleswereobtained
by lumbar puncture (LP) between the L3/L4 and L4/L5
intervertebral space. Except when otherwise noted, a volume
of 10–12mL CSF was collected in polypropylene tubes
followed by centrifugation (2000 × g, 10min, 4◦C) and
storage in smaller aliquots at −80◦C. Plasma was obtained by
the centrifugation (2500×g, 10min, 4◦C) of whole blood in
EDTA tubes (BD, art. nr. 367864). The plasma was aliquoted
into polypropylene tubes and stored at −80◦C pending
analysis. All samples were thawed at room temperature (RT),
if nothing else is declared. The samples used for evaluation
of confounding factors were aliquots from samples sent for
routine diagnostic purposes. All samples were decoded so
that no information could be linked to an individual patient.
2.2. Subjects. Two case control studies assessed the diﬀer-
ences in CSF Aβ42 levels due to diﬀerences in pretreatment,
the ﬁrst study comprised 15 AD and 15 control samples
and the second comprised 20 AD and 20 control samples.
The patients who received the diagnosis of AD fulﬁlled
the DSM-III-R criteria of dementia [20] and the criteria
of probable AD deﬁned by NINCDS-ADRDA (National
Institute of Neurological and Communicative Disorders—
Stroke/Alzheimer’s Disease and Related Disorders Associ-
ation) [21]. Healthy controls were mainly recruited from
senior citizens’ organizations, while a few were spouses of
study patients. Controls were not included if they had a
historyorsubjectiveorobjectivesignsofacognitivedisorder.
The study was conducted according to the provisions
of the Helsinki Declaration and was approved by the ethics
committee of the Universities of Gothenburg and Lund and
the Karolinska Institute, Sweden.
2.3. CSF Analysis. Unless otherwise stated, the CSF Aβ42
concentrations were obtained using the Innogenetics NV
INNO-BIA xMAP technology (INNO-BIA AlzBio3) [22].
For practical reasons some tests were analyzed using the
established Innogenetics enzyme-linked immunosorbent
assay (ELISA) (INNOTEST β-amyloid1–42)[ 23], using a
slightly modiﬁed protocol [24], which has previously been
shown to correlate well with the Innogenetics AlzBio3 assay
[22]. Since preanalytical factors were to be assessed and not
absolute Aβ42 levels, using diﬀerent assays should pose no
problems.Inacasecontrolstudy,theseassayswerecompared
with four other commercially available Aβ42 immunoas-
says from Innogenetics (INNO-BIA plasma Aβ forms)
[25], Meso-Scale Discovery (MSD 96-Well MULTI-SPOT,
Human/Rodent (4G8) Abeta Triplex Ultra-Sensitive Assay)
[26], and The Genetics Company (hAmyloid β42 ELISA)
[27, 28], to evaluate their performance in discriminating
between AD patients and healthy controls. All analyses
were performed according to manufacturers’ instructions;
however, the Innogenetics ELISA was also performed by
replacing the detection antibody with the 4G8 monoclonal
antibody.Thecaptureanddetectionantibodiesforeachassay
aresummarizedinTable 1.Wheneverpracticallypossiblethe
samples for a speciﬁc experiment were run on the same plate
in order to eliminate errors caused by interassay variability.
2.4. Statistical Analysis. Since several variables were found
to be skewed the nonparametric Friedman’s or Wilcoxon
tests were used for pairwise comparisons while the Mann-
Whitney U-test was employed for unpaired comparisons.
The data is presented as median and percentiles (5th
and 95th). Correlation analyses were performed using the
Spearman correlation coeﬃcient (rho). Receiver operating
characteristic (ROC) analyses were performed to evaluate
the discrimination power of the diﬀerent assays using the
area under the curve (AUC). SPSS 15.0 was employed for all
univariate analyses.
2.5. Sample Collection and Assessment of Confounding Factors
2.5.1. Adsorption to Test Tubes and Lumbar Catheter Walls.
Freshly collected CSF from ten diﬀerent subjects was tapped
into glass (Schott, art. nr. 2317103), polypropylene (Sarstedt,
art. nr. 60.549), and polystyrene (Sarstedt, art. nr. 55.476)International Journal of Alzheimer’s Disease 3
Table 1: Properties of evaluated commercially available Aβ assays. The various capture and detection antibodies employed in the diﬀerent
Aβ42 immunoassays. The diﬀerences in antibody epitope recognition and the part of CSF diluted in buﬀer during the incubation render
methodological diﬀerences both qualitatively and quantitatively. aa, amino acids.
Innotest Elisa Innotest Elisa (4G8) The genetics INNO-BIAAlzBio3 INNO-BIAAβ
forms MSD Triplex
Capture
(epitope)
21F12
(42 C-terminal)
21F12
(42 C-terminal)
W02
(aa 5–8)
4D7A3
(42 C-terminal)
21F12
(42 C-terminal)
Not declared
(42 C-terminal)
Detection
(epitope)
3D6
(aa 1–5)
4G8
(aa 17–24)
G2-13
(42 C-terminal)
3D6
(aa 1–5)
3D6
(aa 1–5)
4G8
(aa 17–24)
CSF
(% v/v) 25 25 50 75 75 50
Aβ 1–42 x-42 x-42 1–42 1–42 x-42
tubes. The tubes were incubated at RT for one hour on
a Boule mixer and thereafter stored in a freezer (−80◦C)
pending analysis.
Six samples of CSF were divided into three aliquots of
whichonewasrunthroughalumbarcatheter(Braun-Periﬁx,
art. nr. 4513150), one was run through a lumbar pressure
meter catheter (Mediplast, art. nr. 6061650008), while the
third aliquot was analyzed without any pretreatment.
2.5.2. Incubation, Storage, and Collection of CSF. To test
whether Aβ42 is sensitive to handling at RT, eight freshly
collected samples, within 3 hours after withdrawal, were
divided into two aliquots. The ﬁrst aliquot was analyzed
immediately, while the other was analyzed after 24 hours of
incubation at RT. Six control samples were set on each plate
to adjust the levels according to the interassay variability.
I no r d e rt ot e s ti fA β42 is sensitive to freezing eight
samples of CSF were collected freshly and divided into two
aliquots. The ﬁrst aliquot was analyzed immediately while
the second was stored at −80◦C for at least one week
pending analysis. Two control samples, each analyzed in two
duplicates, were used to adjust for interassay variability. The
samples were analyzed using Innogenetics ELISA.
Data on the long-term storage stability of Aβ42 in CSF at
−80◦C were retrieved from repeated analyses (N = 214) of
an internal quality control sample (aliquots of a large CSF
pool) during 26 months. The control sample was analyzed in
duplicates at each occasion using the Innogenetics ELISA.
To test for the impact of incubation at RT in combi-
nation with freezing, twelve samples of CSF were collected
freshly and divided into seven aliquots of which one was
immediately frozen. The remaining six aliquots were stored
at either +4◦C or RT for four hours, 24 hours or three days
and thereafter frozen pending simultaneous analysis using
Innogenetics ELISA.
Totestforthesensitivityofdiﬀerentprocessesoffreezing,
diﬀerent freezing temperatures, and diﬀerent thawing condi-
tionsfreshlycollectedCSFfromtensubjectswasdividedinto
eight aliquots and analyzed. Two aliquots were tested for the
process of freezing; one was frozen on dry ice/ethanol and
thereafter stored at −80◦C for three days while the other was
immediately stored at −80◦C .T h r e ea l i q u o t sw e r ef r o z e na t
−20◦C at stable temperature, −20◦C in an auto-defrosting
freezer, or −80◦C for three days. Three aliquots were stored
at −80◦C for three days and thereafter tested for thawing in a
fridge (+4◦C), at RT and in a water bath at +20◦C.
To test whether the initial LP conditions inﬂuence the
biomarker level, freshly collected CSF from nine subjects was
either collected at RT or in tubes placed on ice. The samples
were left to incubate for three hours and thereafter frozen at
−80◦C.
2.5.3. Aβ Spinal Chord Gradient. The Aβ42 CSF spinal chord
gradient was assessed by sequentially withdrawing four
fractions of 10mL CSF from seven patients; fraction 1 (0–
10mL), 2 (11–20mL), 3 (21–30mL) and 4 (31–40mL).
2.5.4. Contamination of Blood and Blood-Brain Barrier
Dysfunction. To examine if blood contamination inﬂuence
CSF biomarkers a blood sample was diluted by water and
freeze-thawn in dry ice/ethanol in order to lyse erythrocytes.
Serially diluted blood equivalent to an erythrocyte level of
200, 1000 and 5000/μL (0.004–0.1% v/v) was then added
to 10 diﬀerent CSF samples (95% v/v) and compared with
thecorrespondingwater-dilutedCSF(95%v/v).Thesamples
were analyzed using Innogenetics ELISA.
To test the inﬂuence of blood-brain barrier (BBB)
dysfunction on CSF biomarkers a plasma sample was serially
diluted by water to an albumin level corresponding of
approximately 0.25, 0.50, 1.0 and 2.0g/L (0.625–5% v/v)
when added to 8 CSF samples (90% v/v) with an albumin
level of approximately 0.20g/L. The samples were compared
with corresponding water-diluted CSF (90% v/v). This series
represents diﬀerent degrees of BBB permeability with a
CSF/serum albumin ratio of 5, 11, 18, 30 and 55, respectively
(5 equals the CSF baseline level ((0.20g/L / 40g/L (serum
albumin)) × 1000)). The samples were analyzed using the
Innogenetics ELISA.
2.5.5. The Inﬂuence of an Overnight Fast on Plasma Aβ42
Levels. Blood was withdrawn at three diﬀerent occasions
from nine cognitively healthy subjects to test whether fasting
or subsequent food intake inﬂuences the plasma baseline
Aβ42 levels. Plasma was preferred as opposed to CSF due
to the inconvenience of repeated ﬂuid sampling by LP on
healthy subjects. The baseline blood sample was withdrawn4 International Journal of Alzheimer’s Disease
at nine o’clock in the morning following a nonstandardized
breakfast, the follow-up sample after three weeks at the same
time in the morning following an overnight fast and the
postprandial sample one hour after a standardized breakfast
the same day. The samples were analyzed using Innogenetics
INNO-BIA plasma Aβ forms.
2.5.6. Diurnal Variability. CSF from 14 psychiatrically and
neurologically healthy subjects undergoing knee prothesis
surgery was serially collected by LP with an 18-Gauge Portex
epidural needle at baseline, after four to six hours (mean
5.3 hours) and after 24 hours, for further details on this
procedure see Anckars¨ ater et al. [29]. The samples were
immediately stored at −80◦C pending analysis.
2.5.7. Centrifugation and Heat Denaturation. CSF from ten
subjects was divided into three aliquots each of which one
was analyzed without any pretreatment. The other two
aliquots were centrifuged for ten minutes (2000 × g), at RT
or at +4◦C to evaluate the eﬀect of Aβ precipitation during
centrifugation.Furthermore,18samplesofCSFweredivided
into two aliquots of which one was boiled at 100◦Ci na
heating block for ten minutes. Both samples were thereafter
centrifuged at +4◦C for ten minutes (2000 ×g).
CSF from 15 AD patients and 15 controls were divided
into two aliquots of which one was preincubated for 15
minutes at 100◦C in a heating block. Both aliquots were
centrifuged (2000×g)a t+ 4 ◦C for ten minutes and analyzed
using the Innogenetics ELISA.
2.5.8. Sample Pretreatment Aﬀecting Assay Analyses. Af r e s h
CSF sample was used to assess the impact of incubation at
RT on changes in pH. The baseline pH was measured within
30minutes from LP.
A CSF pool was serially diluted (50%, 25%, 6.25%
and 3.125% v/v) in diﬀerent buﬀe r sa sw e l la si nt h e
provided assay buﬀer. Diﬀerent buﬀer concentrations (10,
50 and 100mM phosphate buﬀered saline (PBS) (pH 7.4)),
and diﬀerent buﬀer substances (PBS, Tris and HEPES (pH
7.4)), were tested for the eﬀect on the measured Aβ42
concentration. Furthermore, the eﬀect on assay performance
at diﬀerent pH was evaluated in 50mM Tris (pH 7.4, 8, and
9). The addition of 0.1% v/v Tween 20, 0.05% v/v Triton
X100 and 0.5mg/mL BSA to 50mM PBS (pH7.4) was used
to further assess the improvement of Aβ42 detection.
2.5.9. Epitope Masking and/or Assay Speciﬁc Variability.
Divergences in measured Aβ concentration levels between
diﬀerent commercially available Aβ42 assays were evaluated
and the assays were compared with respect to how well
they perform in discriminating between AD patients and
healthy controls. CSF from patients with AD (n = 20) and
healthy controls (n = 20) was analyzed using assays from
Innogenetics (ELISA, Abeta forms, and AlzBio3), Meso-
Scale Discovery (Triplex), and The Genetics (ELISA). The
commercial Innogenetics ELISA was also tested by replacing
the detection antibody with the monoclonal antibody 4G8.
Neat and threefold diluted (0.05% Tween 20 in PBS) CSF
sampleswereanalyzedaccordingtotheinstructionsfromthe
manufacturers.
3. Results and Discussion
3.1. Adsorption to Test Tubes and Lumbar Catheter Walls.
The Aβ42 levels were signiﬁcantly altered by storage in
diﬀerent test tubes. The Aβ42 levels signiﬁcantly decreased
when CSF was stored in polystyrene tubes (208ng/L (126–
467)) compared with polypropylene (271ng/L (152–478)),
as previously shown by others [23, 30, 31], rendering a
signiﬁcantly decreased Aβ42 l e v e lo fa sm u c ha s3 5 %( m e a n
decrease 19%; P = .002). The Aβ42 level also decreased when
CSF was stored in glass tubes compared with polypropylene,
however it did not reach statistical signiﬁcance. Some of the
previously reported diﬀerences in absolute values of Aβ42
m i g h tt h u sb ed u et oa d s o r p t i o nt od i ﬀerent test tubes
probablycausedbythehydrophobicnatureofthisanalyte.In
consequence, standardization of collection tubes is necessary
in order to be able to compare absolute concentration values
among diﬀerent centers.
Adhesion of Aβ42 to the lumbar catheter walls during
LP might also render a diﬀerence in analyte concentration
and would urge for standardization. However, two diﬀerent
catheters were tested of which none signiﬁcantly altered the
concentration of Aβ42 as compared with the baseline level.
3.2. Incubation, Storage and Collection of CSF. It is essential
for reliable biochemical analysis that the stability of a
biomarker is thoroughly investigated in order to implement
the appropriate preanalytical handling. Eight CSF samples
were analyzed within three hours from withdrawal and after
24 hours of incubation at RT. No signiﬁcant diﬀerence
between the paired samples was detected in the Aβ42 levels
suggesting that this biomarker is stable when left for at least a
day at RT. Furthermore, no signiﬁcant alteration in the level
of Aβ42, as previously described [32], was found between
fresh CSF and CSF that had undergone one freeze/thaw
cycle. Nor were there any signiﬁcant diﬀerences between the
baseline Aβ42 levels of freshly frozen samples and samples
frozen after incubation at RT or at +4◦C for four hours,
24 hours or three days. These results are in contrast to one
study, which found Aβ42 to be decrease by 20% after two
days incubation at RT, while no diﬀerence was found when
comparing fresh CSF to frozen/thawed CSF [33]. However,
the fresh CSF had been incubated at RT during two days,
which would mean that the level of Aβ42 implemented as a
baseline value was decreased and thus also the Aβ42 level in
the frozen CSF. Furthermore, the study had a very limited
sample size which may contribute to the divergent results.
Another study showed, contradictory to ours, that the Aβ42
concentration was increased after 24 hours of incubation
at RT [34]. However, the CSF was not centrifuged prior to
incubation which seems to aﬀect the outcome, see below.
The storage stability of CSF Aβ42 at −80◦C was assessed
through an internal quality control sample which was
analyzed on a weekly basis during a time period of 26
months. The coeﬃcient of variation (CV) on 214 diﬀerentInternational Journal of Alzheimer’s Disease 5
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Figure 1: The mean Aβ42 variation in CSF during 26 months. An
internal quality control sample was run on 214 diﬀerent occasions
rendering a mean ± SD value (—) of 643 ± 48ng/L and a CV of
7.5%.
runs was 7.5%, which is less than the inter assay CV
(7.7%)reportedbythemanufacturer(InnogeneticsNV)and
consequently signify the storage stability of Aβ42 during the
accounted time period (Figure 1). The storage stability of
Aβ42 in CSF during shorter time periods has previously been
reported further supporting this ﬁnding [35].
No signiﬁcant changes accounting for larger diﬀerences
than the intraindividual assay CV (3.8%) was seen for
neither of the various routes for freezing, the diﬀerent
storage temperatures, nor the diverse thawing procedures.
Moreover, no diﬀerence in Aβ42 concentration was found
when comparing CSF collected and incubated in tubes
placed on ice during the LP procedure compared with CSF
collected and incubated at RT. This is an indication of the
Aβ42 stability and supports the use of this peptide as a
CSF biomarker. However, other proteins may be sensitive
to storage at −20◦C. Storage at −20◦C causes, for instance,
a truncation in Cystatin C revealed by a peptide artifact
identiﬁed by gel electrophoresis and mass spectrometry [36,
37]. Therefore, it is recommendable to store CSF samples at
−80◦C as a precaution to possible future analyses.
3.3. Aβ Spinal Chord Gradient. Since CSF proteins originat-
ing from brain cells may have a decreasing rostro-caudal
concentration gradient, while proteins released from the
leptomeninges and blood derived proteins have a lower
ventricular than lumbar CSF concentration, withdrawal of
diﬀerent CSF volumes might aﬀect the outcome of biochem-
ical analysis [38]. By withdrawing a small volume of CSF
the biochemical composition might only reﬂect that of the
lumbar dural sac and the withdrawal of a too large volume
might inﬂuence the analysis as to increase the concentration
of a brain speciﬁc protein. No spinal chord gradient was
detected for Aβ42 when successively withdrawing four 10mL
portions CSF; that is, the four portions did not signiﬁcantly
diﬀer in their Aβ42 level. Although there was no gradient for
CSF Aβ42 along the spinal chord, it is still recommended to
take a standardized volume of CSF at LP since other proteins
such as albumin [39] and especially neurotransmitters [40]
will be aﬀected.
3.4. Contamination of Blood and Blood-Brain Barrier Dys-
function. It is not uncommon that the CSF gets contam-
inated by blood during the LP procedure [41]. Since the
concentration of proteins in CSF is about 0.5% that of blood
[42] only a minor leakage could lead to an altered biomarker
proﬁle.Furthermore,bloodcontaminationofCSFcouldlead
to an increase in protein degradation already visible after
6 hours of incubation [43]. Therefore, it is important that
contaminated CSF is discarded and that CSF is centrifuged
as soon as possible after LP to get rid of contaminants
invisible to the eye. Consequently, the addition of 0.1%,
0.02% and 0.004% (corresponding to 5000, 1000 and 200
erythrocytes/μL) of blood to CSF should provide reliable
information on the impact of contamination, unnoticeable
totheeye,ontheAβ42 levels.However,nosigniﬁcantchanges
accounting for larger diﬀerences than the intraindividual
assay CV was seen when comparing CSF contaminated with
blood to neat CSF (Figure 2(a)).
Neat CSF was compared with CSF with added plasma,
corresponding to a CSF/serum albumin ratio of 5, 11,
18, 30 and 55, (i.e., a range from normal to pathological
blood-CSF barrier function), and the Aβ42 concentration
in the diluted CSF was signiﬁcantly (P = .008) decreased
by as much as 49% (228ng/L (165–378)) compared with
the neat CSF Aβ42 concentration (433ng/L (291–851))
(Figure 2(b)). One explanation to the decrease might be
a high concentration of several proteins that bind Aβ in
p l a s m a ,s u c ha sa l b u m i n[ 44], α2-macroglobulin [45]a n d
low-density receptor related protein-1 [46], and it might
explain the fact that numerous studies have found no
correlation between CSF and plasma levels of Aβ biomarkers
[32, 47], for review see [48]. It may be important to consider
the albumin ratio when evaluating the concentration of Aβ42
in CSF in disorders with severe impairment of the BBB, such
as acute meningitis [49], due to the impact of plasma on the
measured CSF Aβ levels.
3.5. The Inﬂuence of an Overnight Fast on Plasma Aβ42 Levels.
Even though the absolute CSF Aβ42 values have diverged
among diﬀerent centers the decreased Aβ42 levels in AD
compared with controls have been consistent. The possible
inﬂuence of an overnight fast or food intake on Aβ42 levels
has been brought forward mainly due to inconsistencies in
studies concerning the plasma levels of Aβ [48]. However,
in this study there was no signiﬁcant diﬀerence between
the baseline plasma Aβ42 level compared with either fasting
or postprandial levels. Furthermore, it would thus seem
unlikely that the CSF Aβ levels would be aﬀected when the
plasma levels were not.
3.6. Diurnal Variability. Diurnal variability in CSF Aβ levels
would give cause for a standardized sampling time for
everyday clinical routine. In a previous study, wherein 6mL
of CSF was withdrawn each hour, it was shown that Aβ
had a large diurnal variability [50]. During a time period of6 International Journal of Alzheimer’s Disease
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Figure 2: Boxplots with whiskers representing minutes and max
values. (a) The eﬀect of blood contamination on CSF Aβ42 levels.
The addition of blood to CSF representing an erythrocyte level
of 200, 1000 and 5000/μL of blood did not aﬀect the Aβ42
level compared with neat CSF. (b) The eﬀect a blood-brain
barrier dysfunction on Aβ42 levels. Plasma was added to CSF at
a concentration representing a CSF/serum albumin ratio of 11,
18, 30 and 55. The Aβ42 concentration was signiﬁcantly decreased
(P<. 01) at all added plasma concentrations.
36 hours, the Aβ levels peaked at 12 hours and 23 hours with
troughsatbaselineand25hourswithsigniﬁcantﬂuctuations
of more than 50% within 6 hours. However, no complete
return to baseline values was seen for Aβ. Our data showed
more stable levels with a slight but signiﬁcant decrease of
9.3% (P<. 001) in CSF Aβ42 after 4–6 hours (mean 5.3
hours), which tended to return to baseline levels after 24
hours (4.4% lower than baseline; P = .002).
In this study, our attempt was to reﬂect the variation
in CSF withdrawal time that might be a reality in some
clinical settings. One explanation to the diﬀerence between
our results and the study by Bateman et al. [50]m i g h tb e
that a smaller CSF volume was taken, which may cause less
eﬀect on the CSF dynamics. Even though the CSF Aβ42
level does not seem to be inﬂuenced by circadian rhythms
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Figure 3: Boxplot (whiskers represent minutes and max values) of
measured concentrations of Aβ42 in untreated and heat denatured
CSF. The white boxes represent untreated CSF and dark boxes
represent heat denatured CSF. Each box represents 15 samples (15
AD or 15 controls).
to any greater extent, other analytes might be which would
support a standardized time interval during the day for CSF
withdrawal.
3.7.CentrifugationandHeatDenaturation. Ten samples were
divided into three aliquots in order to test for precipitation
during centrifugation, with and without cooling during the
process. There was a signiﬁcant (P = .002) decrease in the
concentration of Aβ42 in both of the centrifuged samples
(RT 203ng/L (138–340); +4◦C 203ng/L (139–341)) when
compared with the noncentrifuged samples (228ng/L (147–
354)). This indicates that a portion of Aβ42 in CSF might
originate from cells that have undergone lysis that would
precipitate together with the cells during the process of
centrifugation. Furthermore, the Aβ fraction accessible to
the antibody was further addressed by exposing CSF to heat
denaturation. Herein, 18 CSF samples were divided into
one heat exposed aliquot versus one unexposed aliquot and
both were submitted to centrifugation prior to analysis. The
Aβ42 concentration increased signiﬁcantly (P<. 001) in
the heat treated samples (278ng/L (170–471)) as compared
with the untreated samples (210ng/L (127–357)). This result
was replicated in a case control study were the increase
of Aβ42 was larger in the AD patient group (71%, P<
.001) compared with the control group (42%, P<. 001)
(Figure 3). Consequently, the ROC analysis revealed a
decreased discriminating power between AD and controls
after heat treatment (AUC = 0.796) compared with the
untreated samples (AUC = 0.907). The correlation for both
test samples was high (rs > 0.8, P<. 001), when comparing
untreated versus treated samples, indicating methodological
stability.
3.8. Sample Pretreatment Aﬀecting Assay Analysis. Factors
known to aﬀect the solubility and stability of proteins
were investigated for its cofounding eﬀects during analysis.
Diﬀerent buﬀer concentrations (10, 50 and 100mM PBS,
pH 7.4) and diﬀerent buﬀer substances (PBS, Tris andInternational Journal of Alzheimer’s Disease 7
HEPES, pH 7.4) did not aﬀect the CSF Aβ42 measurement
performance compared with the provided assay buﬀer. The
pH of CSF was investigated and found to increase rapidly in
RT from a starting value of pH 7.9 and reaching a plateau at
pH 8.7 already after ﬁve hours. To test if the Aβ42 antibody
binding capacity is altered due to diﬀerences in pH during
analysis, which could be a confounding factor if employing
ab u ﬀer with a low buﬀer capacity, pooled CSF was tested
in three diﬀerent pH systems (50mM Tris, pH 7.4, 8 and
9). Compared with the levels of Aβ42 obtained in provided
assay buﬀer system, the diﬀerent pH tested did not alter
the Aβ42 levels. Furthermore, BSA (0.5mg/mL) and two
diﬀerent detergents (0.05% Triton100 and 0.1% Tween20)
were added to test if the signal of Aβ42 could be improved by
possibly decreasing the negative eﬀects of protein interaction
with the solid surface of the beads and/or the air-liquid
interface. The signal was equally improved for all three
additives (data not shown) as compared with the assay buﬀer
system and the detergent eﬀect was further assessed, what
follows.
3.9. Epitope Masking and/or Assay Speciﬁc Variability. One
hypothesis for the decreased level of Aβ42 in CSF from
AD patients is that plaques in the brain act as sinks for
Aβ42, preventing it from reaching the CSF. In CSF Aβ
may either exist as a free soluble peptide, as oligomers
[51], or bound in complex with carrier proteins such
as α-2-macroglobulin [52], apolipoprotein E (ApoE) [53],
apolipoprotein J (ApoJ; Clusterin) [54, 55], albumin [44],
low-density lipoprotein receptor-related protein-1 (LRP)
[56], and transthyretin [57]. The APOE ε4 allele is the
strongest known genetic risk factor for AD [58, 59]. Carrier
proteins such as ApoE are thought to play a part in the
Aβ clearance and an altered clearance eﬀect, in this case,
is thought to be allele speciﬁc due to a decreased binding
eﬃciencybetweenAβandApoE4ascomparedwiththeother
isoforms [60].
CSF samples were treated with either detergent or heat
denaturation, which has previously been shown to increase
the Aβ42 measureable level [61, 62], to assess the fraction
of possibly bound/epitope masked Aβ42 in proportion to
the free Aβ42 in untreated samples and whether the total
amount of Aβ42 could further improve the diﬀerentiation
between AD and controls. The measured concentration of
Aβ42 increased after the threefold dilution with the detergent
containingbuﬀer.Themoststrikingincreaseswerefoundfor
the xMAP assays AlzBio3 and Aβ forms. The Aβ42 median
concentration for the neat CSF samples varied by more
than a factor of eight, between the diﬀerent assays tested
(Figure 4(a)). The variation in the median is still present
in the diluted samples but markedly reduced to less than
a factor of three. To further investigate the result, the
correlations between the assays were calculated (Table 2).
Almostalltests,bothneatanddiluted,resultedinadiﬀerence
in Aβ42 concentrations between AD and controls with P<
.005. Only the ELISA assay from The Genetics failed to reach
signiﬁcance at this level with P = .086 and P = .017 for neat
and diluted CSF, respectively.
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Figure 4: (a) Boxplot (whiskers represent minutes and max values)
of CSF Aβ42 concentrations using diﬀerent assays. For each kit
the CSF was analyzed twice, neat and threefold diluted in a
detergent-containing buﬀer. Each box represents 40 samples (20
AD + 20 controls). (b) Area under ROC curve for diﬀerent assays
with whiskers representing a 95% conﬁdence interval. Neat, and
threefold diluted CSF are represented by white and dark boxes/bars,
respectively.
The area under the ROC curve was used as a measure
of the discrimination power for the assays (Figure 4(b)).
Most of the assays performed equally well in discriminating
between AD patients and healthy controls and there were
no speciﬁc trend in the performance when the CSF was
threefold diluted. Even though there are large diﬀerences
in Aβ42 concentration depending on which assay is used
most of the correlations between the assays are strong which
indicates that the diﬀerences in measured concentrations
are not due to cross reactivity for other substances than8 International Journal of Alzheimer’s Disease
Table 2: Correlation matrix for the evaluated Aβ assays. The correlation between the levels of Aβ42 in diﬀerent assays. The correlation
coeﬃcients for the neat and diluted CSF samples are shown in the upper right and lower left part, respectively.
Innogenetics Innogenetics The Genetics Innogenetics Innogenetics MSD
ELISA (4G8) ELISA ELISA AlzBio3 Aβ forms Triplex
Innogenetics ELISA (4G8) 1 0.94 0.90 0.87 0.69 0.97
Innogenetics ELISA 0.96 1 0.82 0.93 0.81 0.92
The Genetics ELISA 0.93 0.88 1 0.75 0.53 0.87
Innogenetics AlzBio3 0.92 0.94 0.89 1 0.88 0.84
Innogenetics Aβ forms 0.78 0.86 0.67 0.86 1 0.66
MSD Triplex 0.98 0.96 0.93 0.93 0.77 1
Aβ42. One possible explanation for the variation is that kit
manufacturers have diﬀerent sources for the Aβ42 standard
that is used for calibration. This result highlights the need
for an external Aβ42 control program that would allow
manufacturers to calibrate their assays towards a common
standard.Thereasonfortheincreaseinmeasuredconcentra-
tion of Aβ42 upon dilution is at present unknown but might
involve dissociation of Aβ homo- or heterocomplexes which
w o u l dl i b e r a t em o r eA β42 that are otherwise masked for
detection. If this is true the results from the diluted samples
would more truly reﬂect the total Aβ42 concentration, which
potentially could be an even better biomarker than the
“free” Aβ42 measured in the undiluted samples. However,
there were no dramatic changes in the discriminating power
in the diluted CSF compared with neat samples. Besides,
methodological reasons for the increase cannot be excluded
since the most dramatic changes are for the two assays
based on the xMAP technology (Innogenetics’ AlzBio3 and
Aβ forms). Herein, it is clearly shown that divergences
in absolute Aβ42 levels between diﬀerent centers could be
explained by the fact that diﬀerent ELISAs are utilized
with diﬀerent protocols as well as assay methodologies
(Table 1). However, when diﬀerent centers employ the same
ELISA from the same manufacturer divergences often still
remain [63]. Another factor aﬀecting the Aβ concentration
inconsistency might be the result of a lot-to-lot variability
[64].
Detergent and heat treatments give rise to a similar
increase in the measured level of Aβ42 in the AD groups,
75% and 71%, respectively. In contrast, the detergent
treated control CSF diverged from the heat denatured by
a more pronounced increase (83% versus 42%). Whether
the divergences in the increase of Aβ42 levels between the
two diﬀerently treated CSF samples of the controls and the
discriminating power between neat/detergent CSF compared
with native/denatured samples could be explained by the
diﬀerences in study sample, methodological reasons or
diﬀerences in complex stability needs to be addressed by
further studies.
4. Conclusion
Due to the high between-center variability (possibly caused
by preanalytical and analytical factors) of reported Aβ42
levels in CSF, possible confounding factors were assessed in
relation to the CSF Aβ42 levels. The confounding factors
found to inﬂuence the preanalytical procedures for CSF
collection and sample processing, analytical procedures and
techniques ultimately leading to altered Aβ42 concentrations
are summarized below.
Preanalytical Factors. (i) Increased Aβ42 concentration in
noncentrifuged CSF samples possibly due to a release of the
analyte caused by cell lysis—it is important to centrifuged
CSF within a standardized time interval after LP.
(ii) Decreased Aβ42 levels due to adsorption of analyte
to diﬀerent types of test tubes—standardization of test tubes
used for CSF sampling that is, polypropylene.
(iii) Pretreatment of CSF with detergent-containing
buﬀers or heat denaturation lead to an increase in Aβ42
levels—probablydue to dissociation of Aβ bound to proteins
or release of Aβ from oligomers. For these reasons a
standardization of dilution factors, buﬀer additives and
sample processing is necessary prior to analysis.
(iv) The CSF Aβ42 concentration decreased at the
addition of plasma corresponding to a CSF/serum albumin
ratio of 11–55—probably due to the binding of free Aβ to
plasma proteins.
Analytical Factors. (i) Diﬀerent immuno-assays employing
various antibodies and possibly dissimilar sources for the
calibrator peptides lead to divergences in the absolute
Aβ42 concentration—between center comparisons cannot
be made when employing diﬀerent assays. This problem
cannot be solved until an international Aβ golden standard
is available.
Even though the CSF concentration of Aβ42 does not
seem to be aﬀected by a spinal chord gradient, circadian
rhythms, blood contamination or by storage/thawing condi-
tions other proteins may be. It is necessary to use a standard-
ized protocol to allow for between-center comparisons, for a
detailed protocol see Blennow et al. [9].
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